belimumab

Back in early July, Human Genome Sciences Inc. (HGSI) shares jumped over 230 percent in one day after the pharmaceutical company said its experimental lupus drug had succeeded in a late-stage clinical trial, silencing many of its skeptics. If you decided then that a 230 percent move was all that...